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STEM CELL MOBILIZATION WITH HYC750
de Necochea-Campion, R.1, Scho¨nekess, B.2, Ichim, T.E.3, Josephs, S.4,
Dardov, V.1, Markosi, B.1, Minev, B.1, Carrier, E.1 1UCSD, La Jolla,
CA; 2Orcrist Bio, Inc., Calgary, AB, Canada; 3Medistem, Inc., SanDiego,
CA; 4Therinject, LLC, San Diego, CA
Hyaluronic acid (HA) is a repeating disaccharide polymer having
various biological activities depending on size: high molecular
weight HA performs structural functions, whereas low molecular
weight HA induces systemic cytokine-like effects. HYC750 is
a Good Manufacturing Practices (GMP)-generated HA with an av-
erage molecular weight of 750 kDA that is currently in development
as a hematopoietic stem cell mobilizer.Given the potential for proin-
flammatory activities of various low molecular weight HA fragments
we sought to determine whether HYC750 may possess properties
detrimental to clinical use. Dose-dependent administration of
HYC750 to bone marrow stromal cells, the monocytic cell line
RAW, and differentiated THP-1 cells did not result in alteration
of proliferation or viability. Treatment of said cells with HYC750
did not elicit production ofTNF-alpha as assessed by the L929 assay.
In contrast, LPS treatment induced a dose dependent cytokine re-
sponse. These data, combined with dose escalation studies in
BALB/c mice without induction of inflammatory reactions or ad-
verse effects suggested HYC750 does not cause biological changes
that are conventionally seen with low molecular weight HA admin-
istration. In order to quantify hematopoietic stem cell mobilization
activity, 240 ug/mouse of HYC750 was administered intraperitone-
ally for 5 consecutive days and subsequently marrow, spleen and
blood samples were collected after sacrifice on day 6. A profound in-
crease in the number of stem cells released into the periphery by
HYC750 treatment was determined by forward and side scatter
FACS profiles. When compared to G-CSF mobilization, more
than a 3-fold increase in stem cell antigen (Sca-1) and c-kit positive
cells was observed in animals treated with HYC750, and this treat-
ment was not associated with any decrease in marrow cellularity or
local macrophage activation. These data suggest HYC750 is a novel
mobilizing agent that does not elicit inflammatory responses. Re-
cently, HYC750 received approval to be used in a Phase I, open-
label, single-ascending-dose, safety study in healthy male volunteers,
by the European Competent Authority in Seville, Spain.263
CREATION OF A SEGMENT-BASED ALDEHYDE DEHYDROGENASE ASSAY
AS A BIOMARKER FOR UMBILICAL CORD BLOOD POTENCY
Shoulars, K.1, Gentry, T.2, Page, K.1, Balber, A.2, Kurtzberg, J.1 1Duke
University Medical Center, Durham, NC; 2Aldagen, Inc., Durham, NC
Banked, unrelated umbilical cord blood units (CBU) provide an
option for transplantation in patients where matched adult donors
are unavailable. Current methods for selecting a suitable CBU for
transplantation include examining the human leukocyte antigen
(HLA) matching, total nucleated cell (TNC) count, and viable
CD34 counts on the unit prior to cryopreservation. However, 20%
of patients experience primary graft failure following UCB trans-
plantation (UCBT), suggesting a rapid assay to assess potency on
a thawed CBU prior to the release from the cord blood bank is
needed. Preliminary clinical studies demonstrated that neutrophil
and platelet engraftment as well as overall survival can be predicted
with post-thaw colony forming units (CFU). The usefulness of
post-thaw CFU as a potency assay is limited both by time (14
days) and variability. However, CFUs in fresh cord blood are highly
correlated with the number of cells expressing the enzyme aldehyde
dehydrogenase (ALDHbr cells), which is enriched in hematopoietic
stem cells. Therefore, an ALDHbr assay for segments attached to
CBUs was developed to measure potency for UCBT. Retrospective
studies of transplanted CBUs indicated that engraftment success
could be accurately predicted by the number of ALDHbr cells
infused per kilogram. In order to facilitate prospective studies, the
segment assay was modified to allow HLA matching, CFUs and
the ALDHbr assay to be done from one segment. Blood was with-
drawn from a segment and 3 drops of blood were spotted on
a FTA card for HLA confirmatory typing. The remaining bloodwas washed with 5% dextran/albumin to remove the DMSO. Fol-
lowing removal of 100,000 white blood cells for CFUs, the segment
was assessed using flow cytometry for ALDHbr [Aldecount],
CD45, 7-AAD, Glycophorin A and CD34. Each cell population
was calculated based on the segment TNC. This method reproduc-
ibly assays ALDHbr cells (85% CD34/45 positive) from a single
segment in less than 4 hr while allowing testing of routine parame-
ters of the CBU (HLAmatching, TNC, viable CD34). Furthermore,
the assay produces reliable results when performed at different labo-
ratories (Duke vs. MD Anderson) and on different cytometers (Ac-
curi C6 vs. BD Bioscience Facscalibur). Therefore, this method
will be suitable for further studies on the predictive value of the
ALDHbr assay to measure cord blood potency as an indicator of its
ability to confer neutrophil and platelet engraftment and overall sur-
vival after UCBT.264
THE BIOLOGY AND MEASUREMENT OF HEMATOPOIETIC STEM CELL
POTENCY
Rich, I.N., Hall, K., Harper, H. HemoGenix, Inc, Colorado Springs, CO
Potency is defined as a quantitative measure of biological activity
based on a product’s intended use. There are several reasons why po-
tency is important. It ensures manufacturing consistency and stabil-
ity. It allows prediction and/or assurance for the product’s
performance. It allows evaluation and correlation with the clinical
dose. Most important, it avoids product failure and/or toxicity due
to improper potency. It follows that potency is a predictor; it cannot
be used after the fact as a measure of outcome. For umbilical cord
blood (UCB) transplantation, none of the parameters presently
used to assess a UCB unit (total nucleated cell (TNC) count, viabil-
ity, CD34 or colony count from the CFU assay) can be considered
potency assays because they do not comply with the definition of po-
tency and stem cell potency, in particular. The intended use is en-
graftment of the hematopoietic system. For engraftment to occur,
the transplanted stem cells have to demonstrate their capability to
proliferate. This capability is a measure of stem cell ‘‘quality’’. The
hematopoietic stem cell compartment is not comprised of a single
stem cell population, but a continuum of stem cells with different de-
grees of self-renewal capacity and proliferation potential (PP). These
in turn, will define long- and short-term engraftment potential. The
potency assay must therefore measure PP in order for it to predict
engraftment potential. A UCB stem cell assay has been developed
that measures the PP of two stem cell populations simultaneously,
one primitive (HPP-SP), the other mature (CFC-GEMM). A cell
dose response for both populations is then compared to a UCB ref-
erence standard preparation (a requirement to measure potency).
Proliferation status (stem cell quality) and potential are measured
by their correlation with the intracellular ATP concentration using
a luciferin/luciferase luminescence reporter to produce light that is
measured in a plate luminometer. The resulting linear regression
slope of the dose response is a direct measure of stem cell PP and
therefore potency. Stem cell quality and potency together then
provide the acceptance criteria for the UCB unit to be released for
transplantation. In a single assay, that can be easily validated, all
three parameters, potency, quality and release can be determined si-
multaneously. Without previous knowledge of hematopoietic stem
cell biology, the requirements for a potency assay could not have
been met.265
BONE MARROW TRANSPLANT INDUCES PULMONARY VASCULAR RE-
MODELING IN MICE
Quesenberry, P.J., Del Tatto, M., Dooner, M., Pereira, M., Aliotta, J.M.
Rhode Island Hospital, Providence, RI
Pulmonary complications are common in bone marrow transplant
(BMT) recipients and often of an infectious etiology or attributed to
intensive conditioning regimens. Cases of pulmonary arterial hyper-
tension have been described in the setting of autologous BMT but
are believed to be the result of acquired infections or previously-ad-
ministered chemotherapy. Whether transplanted marrow cells
themselves are toxic to the recipient’s lungs is unknown.
S256 Poster Session IITo address this, non-irradiated female BALB/C mice were trans-
planted with 5-6107 whole bone marrow (WBM) cells from male
BALB/C mice daily for four day on week zero, then again on week
eight (4.5108 cells total/mouse), or an equal volume of diluent
(control). On week 24, transplanted mice received 1000 cGy of
chest-only radiation or no radiation. On week 32, histochemical
and immunohistochemical analyses were performed on recipient’s
lungs.
Bone marrow chimerism was not significantly different in the irra-
diated and non-irradiated cohorts at the time of sacrifice (average
45.11 + 6.25%Y chromosome+, all mice). Recipient lungs contained
few non-hematopoietic donor marrow-derived cells. These cells
were exclusively epithelial (Y+/cytokeratin+), primarily type II pneu-
mocytes (Y+/prosurfactant C+), while no endothelial (Y+/vonWille-
brand+) or vascular smooth muscle (Y+/alpha-actin+) cells were
identified. Irradiated and non-irradiated cohorts had similar quanti-
ties of these cells (0.80 + 0.22% vs. 0.51 + 0.08% Y+/cytokeratin+;
0.37 + 0.08% vs. 0.32 + 0.12% Y+/prosurfactant C+, p. 0.2). Pul-
monary vessel wall thickness-to-blood vessel diameter ratios
(PVWT/D)were significantly increased in the non-irradiated cohort
compared with controls and these ratios were further increased in the
irradiated cohort (141 + 5.75%, 161 + 5.34% of control, p\0.05
comparing all groups).
These data indicated thatmarrow cell infusion alone results in pul-
monary vascular remodeling, and this effect is augmented by radia-
tion injury. These changes are independent of transplanted
marrow cell conversion to pulmonary vascular endothelial, smooth
muscle cells. These studies suggest that transplanted cells may be
lung toxic entities in the setting of clinical BMT.266
MODELS OF STEM CELL TRANSPLANTATION FOR THE REPAIR OF NON-
HEMATOPOIETIC TISSUES
Annett, G., Wirthlin, L., Pepper, K., Sondergaard, C., McGee, J.,
Lindsey, M., Zhou, P., Bauer, G., Nolta, J. University of California,
Davis, Sacramento, CA
Human stem cells from adult sources have been shown, in our lab-
oratory and others, to promote the repair of damaged tissues. Differ-
ent populations of stem cells contribute to the regeneration of
muscle, neural tissue, liver, heart, and vasculature, although the
mechanisms by which they accomplish this are still not well under-
stood. We and others have shown that stem cells home to hypoxic
and/or inflamed areas, and release bioactive factors that can suppress
the local immune system, enhance angiogenesis, inhibit fibrosis and
apoptosis, and stimulate recruitment, retention, mitosis and differ-
entiation of endogenous tissue-residing stem cells. These trophic ef-
fects are distinct from the direct differentiation of stem cells into the
tissue to be regenerated. To actually rebuild a non-hematopoietic
tissue, the differentiated progeny of embryonic or induced pluripo-
tent stem cells will be required. We have focused on improving ro-
dent models in which to examine human stem cell-mediated
disease correction and tissue repair, focusing primarily on liver re-
generation and hypoxic tissue models of peripheral vascular disease
and cardiac ischemia. Most recently we are studying mesenchymal
stem cell–mediated repair of neural damage. We are interested in
the mechanisms by which stem cells of different types and origins
home preferentially into areas of tissue damage, and we seek to im-
prove the robustness. To track cells into the damaged tissues in
vivo, we have labeled them with fluorophore – conjugated iron oxide
nanoparticles and have used novel mouse models that facilitate hu-
man cell detection. We have also used 19F magnetic resonance im-
aging for stem cell tracking with multiple unique perfluorocarbon
nanobeacons, human/murine centromeric FISH, immunohisto-
chemistry and quantitative PCR. Using these technologies, we
have shown that human stem cells migrate from the bloodstream
randomly and in moderate numbers throughout all tissues examined
in cases of chronic disease or following sublethal irradiation, but that
in instances of acute damage, the homing is more vigorous and spe-
cific to the site of damage. Pre-culture in hypoxia dramatically alters
the phenotype and migratory characteristics of human mesenchymal
stem cells.We are applying this knowledge to tissue repair strategies,
to allow enhanced numbers of stem cells to migrate to the areas of
hypoxic damage, to exert trophic effects that initiate revasculariza-
tion and cascades of repair.SUPPORTIVE CARE
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CIDOFOVIR TREATMENT OF BK-VIRUS RELATED HEMORRHAGIC CYSTI-
TIS EARLY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (HSCT)
FOR MALIGNANT DISEASES
Chu, D.T.1, Gulbis, A.M.2, Howell, J.E.2, de Lima, M.1, Matteo, P.1,
Ciurea, S.1, Thall, P.F.1, Champlin, R.E.1, Andersson, B.S.1 1University
of Texas M.D. Anderson Cancer Center, Houston, TX; 2University of
Texas M.D. Anderson Cancer Center, Houston, TX
Background:BK virus infection has been associated with late on-
set hemorrhagic cystitis (HC) after HSCT. Based on data sug-
gesting that cidofovir has activity against BK virus we treated
patients with symptomatic HC and high BK virus titers with ci-
dofovir, we now review the outcome of 32 patients undergoing
this therapy.
Patients andMethods:The patients studied had undergone alloge-
neic HSCT for leukemia (28), MDS (1), lymphoma (2), and ovarian
cancer (1), and presented with UTI symptoms including (any combi-
nation of) hematuria, urgency, and pain, and a high-titer of BK-virus.
Patients received treatment with either once weekly (1-5 mg/kg), or
divided 3  weekly/every other day (0.25-0.5 mg/kg/dose). All pa-
tients received forced hydration. On the once-weekly schedule 22/
23 patients received probenecid and 1/9 in the higher frequency
schedule received probenecid. Semi-quantitative BK virus assay
was performed prior to and following cidofovir.
Results: A total of 32 patients were treated and the median age was
44 years (range, 23-64), with 17 males and 15 females. Donors were
related (n5 13), unrelated (n5 11), haploidentical (n5 2), and un-
related cord blood (CB) (n5 6). The conditioning regimenwasmye-
loablative in 23 pts (72%) and reduced intensity in 9 pts (28%). 24/32
pts (75%) had developed GVHD and were on steroids when diag-
nosed with BK-UTI. Cidofovir was well tolerated with no subjects
developing renal insufficiency. The majority of symptoms were re-
solved within 10 days from cidofovir initiation but the limited num-
ber of subjects precluded a formal comparison between dosing
subgroups (Table 1).
The viral load did not change significantly when assessed at a me-
dian of 24 days after start of cidofovir (median of$3.9 107 copies/
mL). However, patients who were re-assayed at later time points
(median 68 days) had a viral load less than 1%of the initial value (me-
dian 4.9105 copies/mL).
We conclude that cidofovir appears promising as treatment for
BK-virus related hemorrhagic cystitis. The frequent administra-
tion-schedule is relatively easy to administer without the need for
probenecid. More data are needed to determine an optimal cidofovir
dosing schedule, and optimal time to reassess BK virus load by PCR
in allogeneic HSCT patients.
Table 1. Hemorrhagic cystitis symptom response
Hematuria Urgency Cramp/Spasm Pain CBIPre Cidofovir 28 (88%) 27 (85%) 25 (78%) 30 (94%) 13 (41%)
Post Cidofovir 6 (18%) 9 (28%) 1 (3%) 9 (28%) 1 (3%)CBI5 continuous bladder irrigation.268
A PHASE 1 DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY AND
PHARMACOKINETICS OF PALIFERMIN IN PEDIATRIC SUBJECTS WITH
ACUTE LEUKEMIAS UNDERGOING MYELOABLATIVE THERAPY AND AL-
LOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT
Morris, J.1, Neudorf, S.2, Moore, T.3, Shah, A.4, Graham, M.5,
Aquino, V.6, Duerst, R.7, Neidler, M.8, deChateau, M.9, Berger, D.10,
Morris, C.1 1Loma Linda University Medical Center, Loma Linda, CA;
2Children’s Hospital of Orange County, Orange, CA; 3Mattel Children’s
Hospital UCLA, Los Angeles, CA; 4Children’s Hospital, Los Angeles, CA;
5Arizona Cancer Center, Tucson, AZ; 6University of Texas Southwestern
Medical Center, Dallas, TX; 7Children’s Memorial Medical Center, Chi-
cago, IL; 8Pediatric Blood and Marrow Consortium; 9Biovitrum, Stock-
holm, Sweden; 10Amgen, Thousand Oaks, CA
